Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > spring 2003 > from pipe dream to pipeline dream: personalised medicine takes off

PUBLICATIONS

European BioPharmaceutical Review From Pipe Dream to Pipeline Dream: Personalised Medicine Takes Off
Three years ago, at the height of biotech's popularity on Wall Street, the promise of personalised medicine was just emerging. In 2000, only a handful of companies - most notably the then leader of the genomics pack, Millennium Pharmaceuticals - billed themselves as participants in the business of personalised medicine. Since that time, the promise has evolved into a reality with the advent of Genentech's Herceptin and Novartis' Gleevec - both targeted cancer therapies that work very well for patients with the right molecular profile.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

By G Steven Burrill, CEO of Burrill & Company

G Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM).

Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.